Stem Cell Clinic

Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors – BioSpace

By adminJune 24, 2020Stem Cell Treatment

NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Leila Alland and Ms. Jane Wasman to its Board of Directors, effective immediately.

Dr. Leila Alland brings extensive experience in oncology drug development to her role at Cytovia Therapeutics. Dr. Alland is currently Chief Medical Officer at PMV Pharma, a leader in the discovery and development of small molecule therapies targeting p53 mutations, which are prevalent in many cancers. Dr. Alland was previously Chief Medical Officer at Affimed, where she advanced the companys portfolio of clinical-stage immuno-oncology programs. During her career, she has held leadership positions at Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, and has contributed to numerous successful oncology drug approvals over the course of her career, spanning both molecularly targeted and immuno-oncology therapeutic products. Dr. Alland is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research. Dr. Alland obtained her medical degree from New York University School of Medicine, completed her residency in pediatrics at The Childrens Hospital of Philadelphia and her fellowship in pediatric hematology/oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center, and was Assistant Professor of Pediatrics at Albert Einstein College of Medicine. I am very excited to be joining the Board of Directors at Cytovia Therapeutics, said Dr. Alland. Cytovias portfolio of immune therapeutics is steeped in the science of NK cells and the development of powerful new technologies that leverage the ability of NK cells to fight cancer. These novel technologies have the potential to go far beyond current drug development paradigms and make a real difference to individuals living with cancer.

Ms. Jane Wasman is a strategic leader with almost 25 years in the biopharma industry, with extensive U.S. and international experience. Ms. Wasman is Chair of the Board of Directors of Sellas Life Sciences, a board member at Rigel Pharmaceuticals, and serves on the board of NY BIO. Ms. Wasman is Founder and President of JWasman Advisors, (a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations). She previously served as President, International, General Counsel and Chief, Strategic Development at Acorda Therapeutics, where she led long-range planning and development in addition to international expansion and in leadership positions including Vice President at Schering Plough. Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. I am thrilled to be able to joinCytovia's team who is implementing an agile partnership strategy and capital-efficient execution approach, said Ms. Wasman. I believe Cytovia Therapeutics is positioned to become a leading NK company with a differentiated product portfolio, leveraging two strong technologies - CAR NK and NK engager antibodies.

Dr. Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc stated:"We are delighted to welcome two exceptional industry leaders to our boardof directors. Cytovia Therapeutics is at a growth inflexion point where it can fully benefit from Dr. Alland's solid track record in oncology drug development and Ms. Wasman's expertise in corporate and financial transactions."

Media Snippets accompanying this announcement are available by clicking on the images or links below:

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more atwww.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, Inc Sophie Badr Vice President, Corporate Affairs Sophie.badre@cytoviatx.com 1(929) 317 1565

The rest is here:
Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors - BioSpace

Cell Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report 2020-2025 – 3rd Watch News

By adminJune 24, 2020Stem Cell Treatment

The Cell Therapy Market report covers extensive study about the market players operating in the global market. The report offers a complete analysis of the strategies implemented by leading service providers. Additionally, the report contains qualitative and quantitative market evaluation depending on the market segmentation. This report offers an in-depth analysis of the market trends that are influencing the market growth. The report comprises the comprehensive study of geographical regions which may include North America, Europe, Asia Pacific, and the MEA. The report on the Cell Therapy Market is specially designed to provide cutting-edge market intelligence as well as aid investors to take investment estimate decisions.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Exclusive Sample of Report on Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/611

Furthermore, the report covers the PESTLE as well as Porters Five Forces analysis for in-depth comparisons and other significant factors for market analysis. In addition to this, every section of the Cell Therapy research report has offered significant information to provide for service providers to increase their revenue margin, marketing strategy and sales, as well as profit margin. In addition, the Cell Therapy research report offered a comprehensive qualitative as well as quantitative analysis with the several opportunities assessment across the world. Besides, the research report used as a tool for getting extensive market analysis, service providers can recognize the required changes into their operation and gain their position across the global market. In addition, the number of business tactics aids the Cell Therapy Market players to give competition to the other players in the market while recognizing the significant growth prospects.

Likewise, the Cell Therapy research report provides market insights from the huge number of statistics which are collected from robust Cell Therapy Market data such as channel partners, manufacturers, regulatory bodies, as well as decision makers. Similarly, the research report evaluates the market growth rate as well the current market value according to the market dynamics as well as the growth prospects. The market analysis offered in this report is assessed on the basis of market data, market trends, and the number of growth potentials. In addition, it includes an extensive investigation of the market scenario with the in-depth analysis of their major service providers. In addition to this, on the basis of several clients conditions, the Cell Therapy report produces highly customized data that will help regional as well as global service providers to increase their market position over the globe.

Quick Read Table of Contents of this Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

The report offers a complete data analysis about the current trends which have developed and are expected to become one of the strongest Cell Therapy Market forces into coming future. Moreover, the research report offers a holistic overview of the Cell Therapy Market, several factors driving the market growth, as well as the companies involved in the Cell Therapy Market. In addition to this, the Cell Therapy report provides the extensive analysis of the market restraints that are responsible for hampering the Cell Therapy Market growth along with the report offers a comprehensive description of each and every aspects and its influence on the market. Furthermore, the Cell Therapy report provides a detailed value chain analysis of the Cell Therapy Market across the world.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Cell Therapy Market. The feasibility of the new report is measured in this research report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the rest here:
Cell Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report 2020-2025 - 3rd Watch News

Update on FDAs Comprehensive Regenerative Medicine Framework: Looming November 2020 Deadline Preceded by a Flurry of Letters from CBER and a New JAMA…

By adminJune 24, 2020Stem Cell Clinics

As we discussed in our last update on the Food and Drug Administrations Comprehensive Regenerative Medicine Policy Framework back in December 2019 (during the much simpler, pre-COVID-19 world), this coming November will conclude the three-year period of enforcement discretion announced by the agency when it first articulated the policies and goals of this comprehensive framework. In particular, under the dual-track program announced in 2017, the Food and Drug Administration (FDA) has been focused on: (1) clarifying the regulatory criteria for product marketing through guidance and providing support to legitimate product developers through formal and informal interactions; and (2) removing unapproved, unproven, and potentially unsafe products from the U.S. market.

None of the COVID-19-related operational updates provided by the FDA generally or by the Center for Biologics Evaluation and Research (CBER) in recent months has suggested that the November 2020 deadline will be extended or otherwise altered as a result of the ongoing public health emergency, even as certain other enforcement discretion policies have been put into place. Additionally, a recent editorial published by agency leadership and a noticeable increase in Warning/Untitled Letters to persons offering unapproved cellular therapy products, taken together, strongly suggest that folks in this industry that are currently operating outside of the applicable regulatory framework should not expect to be given any additional time to come into compliance.

June 2020 JAMA Editorial Strong Language and No Sign of a Deadline Extension

Multiple statements on the topic of regenerative medicine have been issued by the governing FDA Commissioner as well as CBER Director Peter Marks over the past several years, which indicates how important this area is to the agencys broader public health priorities at the start of the 21st century. The most recent salvo from agency leadership came in the form of an editorial published online by JAMA on June 17, 2020, authored by Dr. Marks and Commissioner Stephen Hahn, who has been in his new job for about six months. Their editorial includes some of the strongest language we have seen to date on the topic of unapproved regenerative medicine products. For example, Dr. Marks and Dr. Hahn state that [d]espite assertions by some individuals to the contrary, these products, whether autologous or allogeneic, are not inherently safe and may be associated with serious adverse consequences. They assert that [t]he increasing number of adverse events being reported following the widespread use of unapproved regenerative medicine therapies at hundreds of clinics across the country make it necessary for the FDA to act to prevent harm to individuals receiving them.

Drs. Marks and Hahn briefly highlight some of the enforcement that the agency has undertaken in this space since 2017 and ask for engagement from both clinicians and patients to help to ensure that instead of remaining unintentionally or intentionally hidden, potentially harmful unapproved regenerative medicine therapies are identified and removed from the market. They then provide basic guidelines for patients and caregivers to use when assessing whether a cellular therapy product is being offered in compliance with applicable laws and FDA regulations. Specifically, they recommend the following key considerations for anyone considering treatment with a cellular product:

Nothing in this newly-published editorial suggests that FDA/CBER will be taking its proverbial foot off the pedal to slow down its efforts towards further oversight of the private stem cell clinic industry after November 2020. To the contrary, the piece could represent one of the last informal warnings those businesses get from the agency before they receive a customized Warning or Untitled Letter or become subject to whatever increased enforcement activity the federal government initiates in this area in 2021 and beyond.

Relatively Large Number of Warning Letters Sent Since January 2020

We previously noted that FDA/CBER appeared to have increased the pace of issuing Warning and Untitled Letters to sellers of unapproved stem cell products during the second half of 2019, with many of those letters involving companies that processed and marketed unapproved umbilical cord blood-derived cellular products. We also reported that the agency had issued a Public Safety Notification on Exosome Products on December 6, 2019, informing the public of multiple reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes. That safety alert also described the unscrupulous conduct of sellers of such products in forceful and direct language, similar to the language used by Dr. Marks and Commissioner Hahn in this months editorial piece.

Over the first half of this year, as we get yet closer to the November 2020 deadline for stem cell clinics and medical practitioners to come into compliance with federal law, there has been a more noticeable increase in the Warning/Untitled Letters issues regarding the marketing of unapproved products that put patients at risk. These include at least nine Untitled Letters issued since January 2020 (which can each be accessed from this CBER webpage) and at least two Warning Letters, one from March and one from June. The Warning Letters in particular include charges that the firms in question were violating current good manufacturing practices (CGMPs) and current good tissue practices (CGTPs) for human cells and tissue products, putting patient safety at risk.

Interestingly, the most recent FDA Warning Letter issued on June 4, 2020 not only cites the recipient for marketing unapproved stem cell products and an unapproved exosome product, but it also states that the unapproved exosome product was being marketed for the treatment and prevention of COVID-19 something the June 17 Marks/Hahn JAMA editorial alluded to generally as well. Given that there are currently no FDA-approved products to prevent or treat COVID-19, any such claims will automatically heighten the enforcement risk to a company or physician engaged in the sale of products for those intended uses.

In addition to the work being done by FDA, moreover, the Federal Trade Commission (FTC) has also been monitoring the commercial marketplace closely and taking various actions to protect consumers from fraudulent COVID-19 products, including a few marketed by stem cell clinics. So far this month, FTC announced on June 4, 2020 that it had issued a 35 warning letters and an additional 30 warning letters on June 18, 2020. The first batch of these FTC warning letters notably included one to a stem cell clinic that, among other things, had claimed that stem cells can be administered intravenously and by inhalation through a nebulizer to treat lung damage caused by COVID-19 without scientific evidence to support the efficacy claim, while the second batch included two letters addressed to marketers of stem cell products.

FDA and the FTC coordinate quite closely on consumer protection matters that implicate both agencies primary missions, as is apparent from the large number of COVID-19 Warning Letters that have been jointly issued by the two agencies since March 2020. So they may very well be coordinating more actively now on the monitoring of stem cell clinics and individual physicians offering unapproved cellular therapies to the general public, as the focus shifts to the next phase of the Comprehensive Regenerative Medicine Policy Framework. The next five or six months should offer everyone more insight into what the enforcement landscape is likely to evolve into once the FDAs enforcement discretion period ends in November. As always, well keep our readers apprised of any notable developments.

[View source.]

Read the original post:
Update on FDAs Comprehensive Regenerative Medicine Framework: Looming November 2020 Deadline Preceded by a Flurry of Letters from CBER and a New JAMA...

Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 – Cole of Duty

By adminJune 24, 2020Stem Cell Clinics

Researchstore.biz has released a new research report titled Global Canine Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which offers a strategic evaluation of the market. The report presents prime parameters such as market size, revenue, sales analysis, and key drivers, and projection of the market by product, area, and use. The report delivers an in-depth analysis of the market with current and future trends. The report recognizes overall growth opportunities, industry drivers, obstacles, latest discoveries, and openings available for newcomers in the global Canine Stem Cell Therapy market.

Competitive Outlook:

The report further contains a competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. In addition, their product portfolio, respective product applications, and product features have been emphasized in the report. The report also provides company shares and distribution shares data for the Canine Stem Cell Therapy market category and global corporate-level profiles of the key market participants.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/48453

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Canine Stem Cell Therapy market.

The study profiles and examines leading companies and other prominent companies operating in the global Canine Stem Cell Therapy industry, covering: VETSTEM BIOPHARMA, VetMatrix, Aratana Therapeutics, Cell Therapy Sciences, Vetbiologics, Regeneus, ANIMAL CELL THERAPIES, Okyanos, Medivet Biologics, Magellan Stem Cells, Stemcellvet,

The far-reaching market study enlists a focused assessment of this business space and the regional landscape of this vertical. As per the report, the Canine Stem Cell Therapy market has established its presence across regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Allogeneic Stem Cells, Autologous Stem cells

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share market growth rate for each application, including: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

This search provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy. The study also predicts the influence of different industry aspects on the global Canine Stem Cell Therapy market segments and regions. It delivers analysis on consumption volume, region-wise import/export analysis, and forecast Canine Stem Cell Therapy market from 2020-2025. At last, the report exhibits an analysis of leading marketing players, product specification, company profiles along with the contact details, production cost.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-canine-stem-cell-therapy-market-2020-48453

Important Aspects of Canine Stem Cell Therapy Market Report:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

The rest is here:
Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 - Cole of Duty

Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers – Stockhouse

By adminJune 24, 2020Stem Cell Clinics

PHILADELPHIA, June 23, 2020 /PRNewswire/ -- Graham Company, one of the country's largest insurance brokerages, today announced a new partnership with Regenexx, a network of leading interventional orthopedics clinics. The partnership gives Graham Company's self-insured clients the option to offer alternative non-surgical orthopedic treatment methods, provided by Regenexx through its expansive network of physicians, as a benefit enhancement for employees. In addition, the partnership will help Graham Company's clients control and reduce overall costs of orthopedic surgery procedures for employees.

According to data from Regenexx, its procedures have effectively intervened on 70% of elective orthopedic injuries and conditions where surgery was previously the only solution.* Regenexx offers a unique approach to treating orthopedic injuries non-surgically through stem cell therapy and other regenerative medicine. Procedures performed by Regenexx's specially trained physician network involve injections of custom orthobiologics, derived from the patient's own cells and natural healing agents, to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70% of orthopedic costs by reducing the number of unnecessary surgeries performed annually.

"At Graham Company, we are committed to identifying solutions to help our clients control escalating health care costs while also enhancing their benefits offerings for employees," said Debra Montella, Graham Company's Vice President of the Employee Benefits Division. "Through this partnership with Regenexx, we are now able to present our self-insured clients with a unique approach that is transforming orthopedic care and driving down costs associated with surgical procedures."

This partnership also benefits the employees of clients with self-funded plans, providing them with alternative non-surgical treatment options to address orthopedic injuries or conditions. Regenexx company data found that when employees are given the choice between an invasive orthopedic surgery or its non-invasive procedure to treat orthopedic conditions, employees chose Regenexx's procedure a majority of the time. Compared to traditional orthopedic surgeries, Regenexx procedures require less downtime for patients and are considered less costly, less invasive and less risky.

"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Graham Company and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."

*This data applies only to elective orthopedic surgery without fracture-related care and acute care trauma.

About Graham Company Graham Company is one of the largest insurance and employee benefits brokers in the country, committed to enhancing employee safety and business viability through an action-oriented approach to risk management. In business for nearly 60 years, Graham Company designs customized and effective property and casualty, surety and employee benefits programs for its clients to protect employees and prevent losses. With offices in Philadelphia, New York City and Washington, D.C., Graham Company became 100 percent employee-owned through an employee stock ownership plan in 2017. Through its innovative insurance and safety training programs, Graham Company is redefining what it means to be an insurance broker. To learn more, visit http://www.grahamco.com.

GRAHAM COMPANY IS AN INSURANCE BROKER AND NOT A MEDICAL CARE PROVIDER. ANY QUESTIONS CONCERNING THIS PROCEDURE SHOULD BE REFERRED TO REGENEXX OR YOUR MEDICAL CARE PROVIDER.

About Regenexx Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. We believe in educating patients, offering options and encouraging people to take an active role in their own treatment. For more information on Regenexx Corporate, visit http://www.regenexxcorporate.com or call 888-547-6667. For more information on the Regenexx procedures, visit http://www.regenexx.com.

View original content:http://www.prnewswire.com/news-releases/graham-company-and-regenexx-announce-innovative-partnership-to-reduce-orthopedic-surgical-spend-for-employers-301081460.html

SOURCE Regenexx

Originally posted here:
Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers - Stockhouse

Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 – 3rd Watch News

By adminJune 24, 2020Stem Cell Clinics

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Cartilage Regeneration market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Cartilage Regeneration Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Cartilage Regeneration market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Global Stem Cell Cartilage Regeneration Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global stem cell cartilage regeneration market report has been segmented on the basis of stem cell type, treatment, end user, and region.

Request Covid 19 Impact

Global Stem Cell Cartilage Regeneration Market: Overview

Stem cell-based therapy is important factor in functional replacement of cartilage regeneration. Stem cells are categorized into three kind of cells namely: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.

Global Stem Cell Cartilage Regeneration Market: Dynamics

Rising adoption of minimally invasive surgery procedures, owing to its benefits such as lower risk and shorter duration for surgery is a key factor expected to drive growth of stem cell cartilage regeneration market over the forecast period.

In addition, increasing incidence of osteoarthritis among population across the globe, which in turn expected to support rising adoption of stem cell cartilage regeneration therapy. This factor is expected to boost growth of the target market over the forecast period.

Moreover, government initiatives such as government agencies which focusing on some policies in order to increase adoption of stem cell therapies is another factor expected to propel growth of target market over the forecast period.

However, higher treatment cost is a key factor expected to restrain growth of the global stem cell cartilage regeneration market over the forecast period. In addition, lack of skilled professionals to access stem cell sourcing, processing, or delivering these technologies is another factor expected to hamper growth of the target market over the forecast period.

Ongoing trend observed in the target market is increasing prevalence of osteoarthritis among population and rising adoption of minimally invasive surgery procedures which is turn expected to support growth of the global stem cell based cartilage regeneration market over the forecast period.

Increasing development of innovative technologies, products, and research and development (R&D) activities by key players are major factors expected to create potential revenue opportunities for the target market over the forecast period. In addition, increasing strategic partnership, merger, and acquisition activities by manufacturers are some other factors expected to create lucrative opportunities for player operating in the global market.

Global Stem Cell Cartilage Regeneration Market: Segment Analysis

Among the stem cell type segments, the mesenchymal stem cells segment is expected to register highest CAGR in the target market, owing to increasing research and development activities by various research organizations across the globe.

Global Stem Cell Cartilage Regeneration Market: Regional Analysis

The market in North America is expected to dominate in the global stem cell cartilage regeneration market in terms of revenue over the forecast period, owing to presence of key players operating in the target market such as Vericel Corporation, Osiris Therapeutics, among others and innovative stem cell based cartilage regeneration product launches, and development of new technologies across various countries in the region. In addition, rising geriatric population, which is more prone to degenerative disorders such as osteoarthritis across US is another factor expected to boost growth of the target market in this region.

The market in Asia Pacific is expected to register significant growth in terms of revenue over the forecast period, owing to stem cell based cartilage regeneration procedures are conducted by various hospital, specialty care, and clinics across India.

Global Stem Cell Cartilage Regeneration Market Segmentation:

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs) Pluripotent Stem Cells (iPSC/ESCs) Mesenchymal Stem Cells (MSCs)

Segmentation by treatment:

Microfracture Osteochondral Transplant Autologous Chondrocyte Implantation Stem Cell Injections

Segmentation by end user:

Hospitals & Clinics Ambulatory Surgical Centers

Quick Read Table of Contents of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

More:
Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - 3rd Watch News

Stem Cell Bond Measure To Be Placed On November Ballot – California Globe

By adminJune 24, 2020Embryonic Stem Cells

On Monday, California Secretary of State Alex Padilla announced that a ballot measure to refund Californias stem cell agency received enough signatures and would be placed on the November 2020 ballot.

The measure, if passed, would refund the California Institute for Regenerative Medicine (CIRM) with a $5.5 billion bond to continue with stem cell research, facility construction, and training. According to the press release, much of the funding would specifically go towards research for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and other central nervous system diseases and conditions.

With 685,534 signatures, 110% of the needed amount, Secretary Padilla can now officially announce the ballot placement once random sampling validates the required amount.

Stem cell research has remained controversial due the use of stem cells from human embryos, or embryonic stem cells. Federal funding for stem cell research was removed by former President George W. Bush in the 2000s, with his successor Barack Obama bringing research back in the 2010s. Despite the controversy, California created its own stem cell research institute after the passage of Proposition 71 in 2004, setting up CIRM. While still controversial, CIRMs immediate need of more funding , compounded by research quickly reducing the need to embryonic stem cells and advances in stem cell treatments for many older patients quickly brought in enough signatures for a refund initiative.

CIRM is close to shutting down, noted stem cell research advocate Gabrielle Hogan. This is badly needed funding that would pay for research for cures or repairing damage caused by Alzheimers and a number of other brain and memory related illnesses.

Its gotten a bad rap from some people because of the use of certain stem cells, but theyve mainly gone away from those that caused a furor twenty years ago. The focus is on saving people and treating people.

If we dont get this bond, which will fund us for a long time to come, then were screwed and we lose out on saving hundreds of thousands of people.

Others have continued to advocate for not continuing funding.

What if you treat someone who doesnt believe in abortion with embryonic stem cells, questioned Rita DAmico, a former nurse who opposed federal reintroduction of funding stem cell research ten years ago. It would be the same as using a medicine or treatment involving something deriving from the pig for a Muslim or Jewish patient, or giving a blood transfusion for a Jehovahs witness.

Its part of the belief, and if theyre still using it for treatments it can single some people out. This was what led it to the federal funding ban when Bush was in office after all.

The ballot measure, which has seen growing support in recent months, is expected to be validated by Secretary Padilla on Thursday.

Evan V. Symon is the Senior Editor for the California Globe. Prior to the Globe, he reported for the Pasadena Independent, the Cleveland Plain Dealer, and was head of the Personal Experiences section at Cracked. He can be reached at evan@californiaglobe.com.

View post:
Stem Cell Bond Measure To Be Placed On November Ballot - California Globe

Trending: Autologous Stem Cell Based Therapies 2020: Global Size, Supply-Demand, Product Type and End User Analysis To 2026 – Weekly Wall

By adminJune 24, 2020Embryonic Stem Cells

LOS ANGELES, United States: QY Research has recently published a report, titled Global Autologous Stem Cell Based Therapies Market Size, Status and Forecast 2020-2026. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Autologous Stem Cell Based Therapies market. It informs readers about key trends and opportunities in the global Autologous Stem Cell Based Therapies market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Autologous Stem Cell Based Therapies market.

Key companies operating in the global Autologous Stem Cell Based Therapies market include , Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe, Autologous Stem Cell Based Therapies

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1889061/global-autologous-stem-cell-based-therapies-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Autologous Stem Cell Based Therapies market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Autologous Stem Cell Based Therapies Market Segment By Type:

, Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells Autologous Stem Cell Based Therapies

Global Autologous Stem Cell Based Therapies Market Segment By Application:

, Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Autologous Stem Cell Based Therapies market.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1889061/global-autologous-stem-cell-based-therapies-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Autologous Stem Cell Based Therapies Revenue 1.4 Market by Type 1.4.1 Global Autologous Stem Cell Based Therapies Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Embryonic Stem Cell 1.4.3 Resident Cardiac Stem Cells 1.4.4 Umbilical Cord Blood Stem Cells 1.5 Market by Application 1.5.1 Global Autologous Stem Cell Based Therapies Market Share by Application: 2020 VS 2026 1.5.2 Neurodegenerative Disorders 1.5.3 Autoimmune Diseases 1.5.4 Cardiovascular Diseases 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends 2.1 Global Autologous Stem Cell Based Therapies Market Perspective (2015-2026) 2.2 Global Autologous Stem Cell Based Therapies Growth Trends by Regions 2.2.1 Autologous Stem Cell Based Therapies Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Autologous Stem Cell Based Therapies Historic Market Share by Regions (2015-2020) 2.2.3 Autologous Stem Cell Based Therapies Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Autologous Stem Cell Based Therapies Market Growth Strategy 2.3.6 Primary Interviews with Key Autologous Stem Cell Based Therapies Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Autologous Stem Cell Based Therapies Players by Market Size 3.1.1 Global Top Autologous Stem Cell Based Therapies Players by Revenue (2015-2020) 3.1.2 Global Autologous Stem Cell Based Therapies Revenue Market Share by Players (2015-2020) 3.1.3 Global Autologous Stem Cell Based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Autologous Stem Cell Based Therapies Market Concentration Ratio 3.2.1 Global Autologous Stem Cell Based Therapies Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Autologous Stem Cell Based Therapies Revenue in 2019 3.3 Autologous Stem Cell Based Therapies Key Players Head office and Area Served 3.4 Key Players Autologous Stem Cell Based Therapies Product Solution and Service 3.5 Date of Enter into Autologous Stem Cell Based Therapies Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Autologous Stem Cell Based Therapies Historic Market Size by Type (2015-2020) 4.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026) 5.1 Global Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 5.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Autologous Stem Cell Based Therapies Market Size (2015-2020) 6.2 Autologous Stem Cell Based Therapies Key Players in North America (2019-2020) 6.3 North America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 6.4 North America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 7 Europe 7.1 Europe Autologous Stem Cell Based Therapies Market Size (2015-2020) 7.2 Autologous Stem Cell Based Therapies Key Players in Europe (2019-2020) 7.3 Europe Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 7.4 Europe Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 8 China 8.1 China Autologous Stem Cell Based Therapies Market Size (2015-2020) 8.2 Autologous Stem Cell Based Therapies Key Players in China (2019-2020) 8.3 China Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 8.4 China Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 9 Japan 9.1 Japan Autologous Stem Cell Based Therapies Market Size (2015-2020) 9.2 Autologous Stem Cell Based Therapies Key Players in Japan (2019-2020) 9.3 Japan Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 9.4 Japan Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Autologous Stem Cell Based Therapies Market Size (2015-2020) 10.2 Autologous Stem Cell Based Therapies Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 10.4 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 11 India 11.1 India Autologous Stem Cell Based Therapies Market Size (2015-2020) 11.2 Autologous Stem Cell Based Therapies Key Players in India (2019-2020) 11.3 India Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 11.4 India Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Autologous Stem Cell Based Therapies Market Size (2015-2020) 12.2 Autologous Stem Cell Based Therapies Key Players in Central & South America (2019-2020) 12.3 Central & South America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 12.4 Central & South America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Regeneus 13.1.1 Regeneus Company Details 13.1.2 Regeneus Business Overview 13.1.3 Regeneus Autologous Stem Cell Based Therapies Introduction 13.1.4 Regeneus Revenue in Autologous Stem Cell Based Therapies Business (2015-2020)) 13.1.5 Regeneus Recent Development 13.2 Mesoblast 13.2.1 Mesoblast Company Details 13.2.2 Mesoblast Business Overview 13.2.3 Mesoblast Autologous Stem Cell Based Therapies Introduction 13.2.4 Mesoblast Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.2.5 Mesoblast Recent Development 13.3 Pluristem Therapeutics Inc 13.3.1 Pluristem Therapeutics Inc Company Details 13.3.2 Pluristem Therapeutics Inc Business Overview 13.3.3 Pluristem Therapeutics Inc Autologous Stem Cell Based Therapies Introduction 13.3.4 Pluristem Therapeutics Inc Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.3.5 Pluristem Therapeutics Inc Recent Development 13.4 US STEM CELL, INC. 13.4.1 US STEM CELL, INC. Company Details 13.4.2 US STEM CELL, INC. Business Overview 13.4.3 US STEM CELL, INC. Autologous Stem Cell Based Therapies Introduction 13.4.4 US STEM CELL, INC. Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.4.5 US STEM CELL, INC. Recent Development 13.5 Brainstorm Cell Therapeutics 13.5.1 Brainstorm Cell Therapeutics Company Details 13.5.2 Brainstorm Cell Therapeutics Business Overview 13.5.3 Brainstorm Cell Therapeutics Autologous Stem Cell Based Therapies Introduction 13.5.4 Brainstorm Cell Therapeutics Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.5.5 Brainstorm Cell Therapeutics Recent Development 13.6 Tigenix 13.6.1 Tigenix Company Details 13.6.2 Tigenix Business Overview 13.6.3 Tigenix Autologous Stem Cell Based Therapies Introduction 13.6.4 Tigenix Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.6.5 Tigenix Recent Development 13.7 Med cell Europe 13.7.1 Med cell Europe Company Details 13.7.2 Med cell Europe Business Overview 13.7.3 Med cell Europe Autologous Stem Cell Based Therapies Introduction 13.7.4 Med cell Europe Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.7.5 Med cell Europe Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Mini-Organ Research Reveals What COVID-19 Does to the Body – Futurism

By adminJune 23, 2020Stem Cell Doctors

In order to understand how COVID-19 spreads throughout the body, ravaging it in myriad ways, doctors are growing miniature balls or organ-like tissue called organoids, and infecting them again and again.

The results, Nature News reports, are particularly troubling: the miniature lungs, livers, kidneys, hearts, intestines all showed signs of damage. The series of studies reveals with shocking clarity that COVID-19 can cause far more than a lung infection.

Of course, thats not exactly news. This harrowing list of survivors and medical workers horror stories gathered by SFGate includes heart attacks, strokes, long-term lung damage, incontinence, skin damage, and other serious complications for supposed mild cases of the coronavirus:

Thats just one of the many, many stories they gathered about the ways a road to recovery from COVID-19 is neither linear nor something that shouldnt be feared.

That said, for all their benefits, organoids are still imperfect. Per Nature, theyre far more simplistic than a full-sized organ. And because theyre not all connected in the same body, doctors can only use them to study the impacts on a single organ in isolation.

We know the cells die but we dont know how, Weill Cornell Medicine stem cell biologist Shuibing Chen told Nature of her study on miniature lungs.

Even though questions remain, its clear those impacts are serious. Various studies found that the coronavirus caused serious damage in several organs, and may lead to indirect damage in others. It also became clear that the coronavirus can infect and spread through blood vessels, leading to a more serious, widespread case.

To figure that out, biologists will need to develop more sophisticated and realistic organoids and try their experiments again, Nature reports.

It is too early to say how relevant they are, Bart Haagmans, an Erasmus MC virologist who ran a study on gut organoids, told Nature.

See the original post:
Mini-Organ Research Reveals What COVID-19 Does to the Body - Futurism

Who is Nick Cordero and how is he doing after his coronavirus battle? – The Sun

By adminJune 23, 2020Stem Cell Doctors

BROADWAY star Nick Cordero contracted coronavirus on March 20 of this year according to his wife Amanda Kloots.

The Tony Award-nominated actorfor Bullets over Broadway has been in the ICU since late March, with his other half keeping fans updated on his progress.

Earlier this year in May, Amanda tearfully revealed that Nick's condition was "going a little downhill."

Nick Cordero is a Canadian Broadway actor.

The 41-year-old has performed in the likes of A Bronx Tale The Musical, Waitress, and Rock of Ages.

He has collected several accolades for his theatre work over the years from the Outer Critics Circle and the Theatre World Awards.

Nick caught coronavirus earlier in March this year and has faced a series of ups and downs since he contracted the virus.

He was hospitalized in ICU after doctors first misdiagnosed him with pneumonia.

Nick has suffered a variety of complications as a result of COVID-19.

Doctors were not only forced to amputate his right leg because of blood clots, but the Broadway star has also had to undergo stem cell treatment to strengthen his lungs.

Nick's wife Amanda, who is single-handedly raising their one-year-old son Elvis while Nick is ill, regularly takes to Instagram to update fans on his condition.

In May, Amanda tearfully shared that Nick's condition was worsening.

"Nick has had a bad morning. Unfortunately, things are going a little downhill at the moment," she shared.

She added "I know that this virus is not going to get him down.

"This is not how his story ends. So just keep us in your thoughts and prayers, thank you."

A week beforehand, she announced that Nick was finally conscious after a month-long coma.

"This infection that is leftover from when he went into septic shock the last time is still in his lungs and just kind of sitting there. They are doing everything they can to clean it out every day but its just not getting better.

The mom-of-one also told fans doctors could "lower his vent settings" once the infection goes away.

That will begin the process of trying to get him breathing on his own.

She added: They are cleaning him out every day and hes on antibiotics, so it can happen and its gonna happen because like Ive said from the beginning, the doctor told me from the beginning, if we have a positive attitude, there are options.

"This infection is gonna go away and he is gonna get off that ventilator. And thats the only mindset that I have right now.

Nick is fighting for his life every day in that ICU and I know he isnt giving up. Were not giving up. Nobody is giving up.

Amanda, 38, recently updated fans that husband Nickhad a "great day" after visiting the actor at Cedars-Sinai hospital in LA on Sunday.

She told her Instagram followers: "He was having such a great day.

"He was more alert than I've seen him in a while and he was really following [with] his eyes a lot."

Amanda also revealed the sweet "little tradition" she has during her hospital visits to see Nick - playing and singing along to seventies track Our House by Crosby, Stills, Nash & Young.

She added: "I say a big prayer, hold his hand and give him a kiss and tell him we will live together in our house one day and keep fighting and it's going to happen."

Nick has spent a total of 82 days in ICU since he was infected with the coronavirus.

Nick's good day comes as a morale boost after Amanda revealed that a CT scan on his lungs confirmed that he would not survive a lung transplant.

Exclusive

"You feel like sometimes there's lots of hope and then sometimes there's not as much hope. We're basically trying to see if we can get him stable and strong enough to have more options," she said.

"It's monotonous and hard on a daily basis - very, very hard."

Read the original here:
Who is Nick Cordero and how is he doing after his coronavirus battle? - The Sun